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Thymidylate synthase (TS) is the rate-limiting enzyme in the
production of thymine nucleotides, methylating deoxyuridine
monophosphate (dUMP) to form deoxythymidine monophosphate
(Peters et al, 1995). Inhibition of the enzyme is one of the main
modes of action of the chemotherapeutic agent, 5-fluorouracil
(5FU) (Thomas and Zalcberg, 1998). The drug is metabolised to
form fluorodeoxyuridine monophosphate (FdUMP) which binds
to TS, in competition with dUMP, to form a complex that deacti-
vates the enzyme (Thomas and Zalcberg, 1998). The relation
between TS and 5FU has led to a wealth of research regarding the
enzyme’s role in pre-existing and inducible resistance to the
chemotherapeutic drug. With few exceptions (Findlay et al, 1997),
existing data suggest increased tumour expression of TS protein
predicts for a poorer response to 5FU in advanced colorectal carci-
noma (CRC) (Peters et al, 1994; Johnston et al, 1995; Leichmann
et al, 1995; Aschele et al, 1999; Paradiso et al, 2000). However,
there are still unresolved issues regarding TS expression in CRC
and its relation to 5FU therapy. 
Firstly, most previous studies of TS protein expression and 5FU
response had only analysed primary tumour tissue (Johnston et al,
1995; Findlay et al, 1997; Paradiso et al, 2000) whereas it is
metastatic tumour that is targeted by 5FU therapy in patients with
advanced CRC. We are aware of only two previous studies
comparing TS expression between primary and metastatic tumour
tissue (Peters et al, 1994; Aschele et al, 2000) and the two studies
have produced conflicting results. 
Previous studies of TS protein expression in CRC in vivo have
assessed such expression with either catalytic assays, FdUMP
binding assays and/or ELISA analyses (Peters et al, 1995).
However, one criticism of all these techniques is the inability to
exclude TS expression of non-carcinoma cells, e.g. fibroblasts and
inflammatory cells, in the samples analysed. Immunohistochemical
assessment of TS protein expression provides an obvious method to
address this problem. Until now, studies using this technique have
only assessed cytoplasmic expression of the enzyme (Johnston et al,
1994, 1995; Suzuki et al, 1998; Yamachika et al, 1998; Paradiso
et al, 2000). Despite the fact that nuclear staining has also been
recorded (Johnston et al, 1991), we are unaware of any work into
the clinicopathological significance of nuclear expression of TS in
vivo. The presence of TS in the nucleus is of particular interest in
light of the recent demonstration that TS protein and p53 mRNA
form a biologically active complex and speculation that this
complex may be localised within the nucleolus (Chu et al, 1999).
There has also been interest in associations between TS and p53
on a more clinical level. At least two previous studies have shown
that p53 protein expression may be used to supplement tumour TS
protein expression as a predictor of response to 5FU therapy (Lenz
et al, 1998a; Paradiso et al, 2000). Whether there is any relation
between nuclear TS protein expression and p53 protein expression
in vivo and whether the two may supplement one another in
predicting for response of advanced CRC to 5FU therapy are
unknown. 
The aims of the following study were, therefore: (1) to confirm
and characterise the nature of nuclear expression of TS in human
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UK. tissue in vivo, concentrating on the colorectum; (2) to assess
whether TS nuclear expression has any relation to clinicopatholog-
ical features of CRC; (3) to study the relation between primary and
metastatic tumour nuclear expression of TS protein; (4) to assess
the relationship between TS nuclear protein expression and p53
protein expression in vivo; and (5) to study how these expressions
relate to response to 5FU therapy for advanced CRC. 
MATERIALS AND METHODS 
Cases 
The 52 patients studied had consented to participate in a study
of protracted venous infusional 5-fluorouracil (PVI-5FU) for
metastatic CRC (Jodrell et al, 2001). None of these patients had
previously received any chemotherapeutic agents. The dose of
5FU that was used was 300 mg m–2 day–1 for 26 weeks and the
patients had all started their chemotherapy between August 1995
and July 1997. This provided a median follow-up of 22.2 months
(range: 16.8–28.5 months). Response to chemotherapy was
defined, according to standard UICC guidelines, as complete
response (CR), partial response (PR), no change (NC) or progres-
sive disease (PD) (Hayward et al, 1977). Survival data was also
collected for all 52 patients. Tissue blocks from the primary carci-
noma and, where available, metastatic carcinoma (excluding
lymph node metastases), of each patient were retrieved from the
archival files of the Departments of Pathology at the University
of Edinburgh Medical School, the Western General Hospital in
Edinburgh, St John’s Hospital in Livingston and the Royal
Victoria Hospital in Kirkcaldy. Haematoxylin and eosin-stained
sections of each primary tumour were reviewed by a gastrointestinal
histopathologist (NW) to ensure uniformity in the assessment of the
following pathological features: Dukes’ stage, differentiation – based
on guidelines released by the Royal College of Pathologists (Quirke
and Williams, 1998) – and extracellular mucin production (abundant
production was defined as extracellular mucin occupying > 50% of
the tumour). Right-sided tumours were defined as those arising in
the caecum, ascending colon or transverse colon, whereas left-
sided tumours were defined as those arising in the descending
colon, sigmoid colon or rectum. 
Immunohistochemistry 
A number of 4 µ m thick sections were cut from the tissue blocks,
dewaxed and rehydrated. For TS immunostaining, antigen
retrieval was carried out using Vector antigen retrieval fluid
(Vector Laboratories, Peterborough, UK) and microwaving at full
power for 10 min. Sections were pre-treated with 3% hydrogen
peroxide for 10 min followed, after the antigen retrieval, by an
avidin-blocking reagent (10% egg white; Sigma, Poole, UK) for
30 min and then the TS106 antibody to TS (from the laboratory of
PGJ) at a dilution of 1:200 for 60 min. Visualisation was achieved
by incubation with a 1:200 dilution of goat anti-mouse antibody
(Vector Laboratories) for 30 min, followed by a streptavidin–biotin
peroxidase complex (Dako, Ely, UK) for 30 min and finally
diaminobenzidine (0.5 mg m–1) for 5 min. For p53 immunos-
taining, the same protocol was used as for TS except 0.1 M citrate
buffer (pH6) was used instead of Vector antigen retrieval fluid, and
the primary antibody used was the DO-7 antibody to p53
(Novocastra, Newcastle, UK) at a dilution of 1:75. For Ki67
immunostaining, the same protocol was used as for p53 except the
primary antibody used was the MM1 antibody to Ki67
(Novocastra) at a dilution of 1:100. Mayer’s haematoxylin was used
to counterstain the TS, p53 and Ki67 immunostained sections. A
CRC found to express high nuclear levels of TS protein during
preliminary studies was used as a positive control for TS immunohis-
tochemistry. A CRC known to show p53 mutation and p53 protein
overexpression was used as a positive control for p53 immunohisto-
chemistry. A normal tonsil was used as a positive control for Ki67
immunohistochemistry. When present adjacent to tumour, lymphoid
germinal centre cells and normal basal crypt colonocytes served as
internal positive controls for both TS and Ki67 immunostaining.
Finally, negative controls (i.e. lacking primary antibody) were
included in each run of immunohistochemistry. 
TS mRNA analysis 
RNA was isolated, as previously described (Gilmore et al, 1998),
from tissue blocks of 10 of the 52 primary CRCs. Genomic DNA
was removed from 2 µ g of each RNA sample by digestion with
DNase I, amplification grade (Gibco-BRL, Paisley, UK) according
to the manufacturer’s instructions. The RNA was then reverse tran-
scribed using random hexamers as previously described (Horikoshi
et al, 1992). Real-time quantitative polymerase chain reaction (PCR)
amplification was performed using target-specific, doubly labelled
fluorogenic probes with the ABI Prism 7700 Sequence Detection
System (PE Applied Biosystems, Foster City, USA). TS primers and
probe were selected with Primer Express software version 1.0 (PE
Applied Biosystems). The TS probe was labelled with 6-carboxy-
fluorescein (5′ -end) and 6-carboxy-tetramethylrhodamine (3′ -end).
The specificity of the chosen sequence was confirmed by conducting
a BlastN search (GenBank). The expression of the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene was used as an internal
standard using Pre-Developed TaqMan Assay Reagents for this gene
(PE Applied Biosystems). The reactions were performed on an ABI
Prism 7700 Sequence Detector using the standard PCR conditions
recommended by PE Applied Biosystems for 60 cycles. During the
PCR reaction, the reporter signal is normalised to an internal passive
reference dye (ROX) to correct for any non-PCR-related fluctuations
in fluorescence signal. The cycle number (CT) at which the
normalised fluorescent signal crosses a threshold set at 10 times the
background fluorescence is related to the quantity of input DNA by
an equation of the form: CT = – mlog(input DNA) + k, where m and
k are constants for a particular primer/probe set. CT values for the
amplification of TS and GAPDH cDNAs were obtained for triplicate
aliquots of each sample. Using serial dilutions of standard DNA
samples, equations relating CT to the quantity of input DNA were
established for TS and GAPDH, from which relative TS and
GAPDH expression levels in each sample were determined. For TS,
a DNA fragment containing the TS coding region was used as the
reference standard. For GAPDH, cDNA prepared from the NCI-
H630 colorectal cell line was used as the reference standard. That
increased expression of GAPDH has been demonstrated in some
human carcinomas, e.g. lung, breast and cervix (Revillion et al,
2000), suggests it may be suboptimal for use as a housekeeper gene
for the study of these cancers. However, we are unaware of any data
showing GAPDH expression to be up-regulated in CRC. Further,
such up-regulation is associated with wide intertumoural variation of
GAPDH mRNA levels (Revillion et al, 2000) whereas there was no
obvious variation in GAPDH expression amongst the CRCs we
studied. 
1938 NACS Wong et al 
British Journal of Cancer (2001) 85(12), 1937–1943 © 2001 Cancer Research CampaignScoring 
All TS-stained sections were assessed blindly and independently by
2 histopathologists (NW and AML). Both the percentage of posi-
tively stained nuclei and a histoscore were calculated for each case.
Calculation of the histoscore (range of 0–300) – based on that used
in the immunohistochemical assessment of oestrogen receptor
expression (McCarty et al, 1985) – is explained in the legend for
Figure 1. The percentage of positively stained nuclei was assessed
semi-quantitatively by low to medium power histological examina-
tion (5–10 × objective) of all the tumour present on a section;
percentages were rounded off to the nearest 5%. Assessment of the
intensity of nuclear staining was made against an illustration
showing examples of weak, moderate and strong intensity staining
(Figure 1). The final TS histoscore used for each case was the mean
of the 2 observers’ individual scores. p53 immunostaining was
scored by recording the percentage of nuclei showing strong posi-
tive staining from counting 500 carcinoma cells and then allocating
each case to one of the following groups: I (< 10%); II (10 – 49%);
III (50 – 89%); IV (90 – 100%). Ki67 immunostaining was scored
by recording the percentage of nuclei showing positive staining
from counting 500 carcinoma cells. 
Reproducibility and statistical analyses 
All 76 TS-stained sections were re-scored by one of the observers
(NW) to enable a calculation of intraobserver reproducibility. To
assess the degree of variation of TS nuclear expression within any
one tumour, five of the 52 primary carcinomas were selected at
random and three additional tumour blocks retrieved for each of
the five cases. Sections from these blocks were cut, stained with
the TS antibody and scored. Kappa values were calculated to
express intra- and interobserver reproducibilities using the
computer software package MedCalc v5.0 (MedCalc Software,
Mariakerke, Belgium). Mann–Whitney U tests and Spearman rank
correlation tests were performed using the computer software
package SPSS v7.5.1 for Windows 95 (SPSS Inc, USA). Both 2-
tailed Fisher’s exact tests and χ 2 tests were performed using the
computer software package Epi Info v6.04b (Centers for Disease
Control & Prevention, Atlanta, USA). The relation of TS
histoscore to patient survival was studied using standard
Kaplan–Meier and logrank test analyses. 
RESULTS 
Clinicopathological details 
Clinicopathological details of the primary tumours of the 52
patients (median age 60 years, range 33–77 years) are shown in
Table 1. Non-nodal metastatic tissue was available for study from
24 patients: 13 liver metastases; seven omental/peritoneal metas-
tases; and four ovarian metastases. 
TS immunohistochemistry 
Immunohistochemical staining with TS antibody showed strong
nuclear positivity in the germinal centres of secondary lymphoid
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Figure 1 Examples of (A) strong, (B) moderate, and (C) weak intensity TS nuclear staining in colorectal carcinomas (all × 100 obj). TS histoscore =
(percentage of tumour cells showing strong intensity staining × 3) + (percentage showing moderate intensity staining × 2) + (percentage showing weak intensity
staining × 1). For example, a tumour with 20% of its cells showing strong intensity staining, 30% showing moderate intensity staining, 30% showing weak
intensity staining and 20% showing no staining would be given a histoscore of (20 × 3) + (30 × 2) + (30 × 1) = 150 
Table 1 Clinicopathological features of 52 patients and their relation to TS
histoscore 
Clinicopathological Subgroups  Mean  TS  P
feature (no of patients) histoscore valuea
Sex Male (34) 70.0 0.39 
Female (18) 72.5 
Site Right (20) 95.0 0.08 
Left (32) 66.3 
Dukes’ stage B (11) 72.5 0.85b
C (28) 68.8 
D (13) 70.0 0.96b
Differentiation Well (2) 65.0 0.75c
Moderate (43) 68.8 
Poor (7) 90.0 0.15c
Abundant extra  Yes (10) 90.0 0.03 
cellular mucin No (42) 67.5 
aMann–Whitney U test. bDukes’ B compared with Dukes’ C tumours, and
Dukes’ C compared with Dukes’ D tumours. cWell differentiated compared
with moderately differentiated tumours, and moderately differentiated
compared with poorly differentiated tumours.follicles and in the basal third epithelial cells of normal colonic
crypts (Figure 2). When present in CRCs, strong and moderate
intensity nuclear staining was often associated with prominent
cytoplasmic staining (Figure 1). A formal correlative study of
nuclear versus cytoplasmic expression of TS was not considered
valid, as our immunostaining protocol had been specifically
designed to optimise nuclear and not cytoplasmic staining. 
TS histoscores 
There was good intraobserver (Spearman rank correlation coef-
ficient 0.83, kappa coefficient 0.62) and interobserver repro-
ducibility (Spearman rank correlation coefficient 0.75, kappa
coefficient 0.52) in the calculation of TS histoscores. For any one
of the five tumours used to test intratumoural variation of TS
nuclear expression, there was a maximum difference in TS
histoscore of 15 amongst sections from four tumour blocks. TS
histoscore showed a significant, positive correlation (Spearman
rank correlation coefficient 0.71, P = 0.022) with TS mRNA
expression measured from 10 primary CRCs (Figure 3). 
The distribution of TS histoscores amongst the 52 primary
carcinomas is shown in Figure 4; the median TS histoscore was
70. The relation of TS nuclear expression to different clinicopatho-
logical features of the 52 cases of primary CRC is shown in
Table 1. Of all the features studied, only the presence of abundant
extracellular mucin showed a statistically significant association
with TS nuclear expression. 
There were no differences in TS histoscores between liver and
other sites of metastases (data not shown). Amongst the 24 pairs of
primary and metastatic tumour, the latter – median TS histoscore
105 – showed significantly greater nuclear TS expression than
primary tumour – median TS histoscore 70 – (Mann–Whitney
U test, P = 0.01). The relationship between primary and metastatic
tumour nuclear TS expression is shown in Figure 5. There was a
significant positive correlation between the TS histoscores of
primary and matched metastatic tumour (Spearman rank correla-
tion coefficient 0.62, P = 0.001). Further, nine of the 13 (69%)
primary tumours with below median (< 70) TS histoscores had
matched metastatic tumour TS histoscores of below the median
(< 105), and nine of the 11 (82%) primary tumours with above
median TS histoscores had matched metastatic tumour TS
histoscores of above the median (χ 2 test, P = 0.04). 
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Figure 2 TS immunostaining (all × 20 obj): (A) normal colonic mucosa showing nuclear staining confined to the lower third crypt colonocytes; (B) lymphoid
follicle showing nuclear staining restricted primarily to germinal centre cells 
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Figure 3 Relationship between TS histoscores and TS mRNA expression
measured by real-time quantitative PCR from 10 primary colorectal
carcinomas. A line of best fit is also shown Response to 5FU therapy and survival 
Of the 52 patients, 16 (30.8%) showed CR or PR, 18 (34.6%)
showed NC and 18 (34.6%) showed PD. 12 (75%) of the 16
responding patients had primary tumour TS histoscores of less
than the group median (i.e. 70) while four (25%) patients had
primary tumour histoscores of greater than 70. By contrast, 16
(44%) of the 36 non-responding patients had primary tumour TS
histoscores of less than the group median while 20 (56%) patients
had primary tumour histoscores of greater than 70 (χ 2 test, P =
0.04). The proportion of patients with primary tumour TS
histoscores of greater than 70 increased with decreasing response
to 5FU: 25% of CR/PR patients, 44% of NC patients and 67% of
PD patients (χ 2 test, P = 0.05). Finally, the median TS histoscore
(60.0) of carcinomas that demonstrated a response to 5FU (CR and
PR) was less than that (92.5) of carcinomas showing progression
(PD) though this trend just failed to reach statistical significance at
the 95% level (Mann–Whitney U test, P = 0.06). Assessing TS
expression using only the percentage of positively stained primary
tumour nuclei failed to show an obvious difference between
responding and non-responding patients (data not shown). None of
the clinicopathological features of the primary tumours shown in
Table 1 were significantly associated with 5FU response (data not
shown). The proportion of patients with metastatic tumour TS
histoscores greater than the group median (i.e. 105) increased with
decreasing response to 5FU: 29% of CR/PR patients, 43% of NC
patients and 80% of PD patients. However, this trend failed to
reach statistical significance (χ 2 test, P = 0.09). Survival data was
available for all 52 patients. There were no significant associations
between TS histoscore and cause-specific or overall survival (data
not shown). 
p53 and Ki67 data 
There were 15 primary carcinomas in p53 group I, 11 in group II,
11 in group III and 15 in group IV. There was no obvious relation
between TS histoscore and p53 group amongst either primary or
metastatic carcinomas (data not shown). Comparing primary carci-
nomas showing or not showing p53 overexpression (defined as
>10% nuclear staining, i.e. groups II–IV) with those showing TS
histoscores greater or less than the group median also failed to
demonstrate any significant association (χ 2 test, P = 0.53). 
The median Ki67-labelling index amongst the 52 primary carci-
nomas was 45% (range 10–91%). There was no obvious relation
between TS histoscore and Ki67-labelling index (data not shown).
There was no significant association between Ki67-labelling index
and response to 5FU (data not shown). 
DISCUSSION 
This study has demonstrated that TS is expressed within the nuclei
of normal colonocytes, normal lymphoid cells and colorectal
adenocarcinoma cells. The prominence of nuclear expression in
the base of normal colonic crypts and in the germinal centres of
lymphoid follicles is in keeping with these sites representing areas
of active cell proliferation and, hence, DNA synthesis. Current
literature on the subcellular localisation of TS in human cells in
vivo is lacking. However, previous studies have demonstrated the
presence of the enzyme in the nuclei of rat hepatoma cells using
immunogold electron microscopy and autoradiography (Samsonoff
et al, 1997), and along the nuclear periphery of yeasts using
immunofluorescence analysis (Poon and Storms, 1994). The signifi-
cance of this subcellular localisation is uncertain but, as previously
mentioned, TS protein and p53 mRNA form a complex which is
speculated to have a nucleolar location (Chu et al, 1999). TS protein
is also known to bind to other mRNAs, e.g. c-myc mRNA (Chu
et al, 1996), but whether and how nuclear TS regulates expression
of their corresponding proteins remains to be determined.
Our histoscore technique was shown to be reproducible and its
ability to quantify nuclear expression of TS supported by good
correlation with TS mRNA expression measured using real-time
quantitative PCR. The importance of considering intensity of TS
immunostaining is demonstrated by our failure to show an associ-
ation between 5FU response and TS expression assessed by calcu-
lating only the percentage of stained nuclei. Interestingly, the study
of metastatic CRC that failed to demonstrate a correlation between
response to 5FU or Tomudex (another TS inhibitor) and TS protein
expression had quantified the latter by assessing only the
percentage of tumour area showing immunogold staining (Findlay
et al, 1997). The validity of our histoscore technique is further
supported by the fact that the positively skewed distribution of TS
histoscores seen amongst our carcinomas (Figure 4) is similar to the
distributions (our analysis of the authors’ data) of TS expression
Nuclear TS expression and colorectal carcinoma  1941
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Figure 4 Histogram showing distribution of TS histoscores amongst 52
primary colorectal carcinomas 
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Figure 5 Scatterplot of TS histoscores of 24 matched cases of primary and
metastatic colorectal carcinoma. A line of unity is also shown measured amongst primary CRCs using FdUMP binding (Larsson
et al, 1998; Sanguedolce et al, 1998) or enzyme activity assays
(Edler et al, 1997). The disproportionate number of carcinomas
lying in the upper tails of these distributions is of particular
interest as they may represent a distinct subpopulation with
regards to TS protein expression. All of our 3 carcinomas
(patients’ ages: 33, 52 and 77 years) with TS histoscores of greater
than 190 were right-sided and showed prominent extracellular
mucin, features that are characteristic of microsatellite instability
(MSI)-associated CRCs (Toft and Arends, 1998). Therefore,
although the effect of MSI on 5FU response remains controversial
(Carethers et al, 1999; El Saleh et al, 2000; Hemminki et al, 2000),
it would be interesting to formally study the relations between TS
expression, MSI and 5FU response in CRC in vivo. 
Our finding that secondary CRC tissue expresses greater
nuclear TS protein than primary tissue differs from the results of
the 2 existing studies on this matter. Peters and colleagues found
no consistent differences in TS expression between primary and
secondary CRC tissue (Peters et al, 1994). However, these investi-
gators assessed TS expressions by catalytic and FdUMP binding
assays rather than immunohistochemistry, and only 14 pairs of
tissue were studied compared with 24 in our study. Using an
immunohistochemical method on 27 pairs of tissue, Aschele and
colleagues reported a lack of correlation of cytoplasmic TS protein
expression between primary and metastatic CRC tissue, and
overall higher expression in the former (Aschele et al, 2000).
While it is uncertain why our findings are diametrically opposite
to those of Aschele and colleagues, this discrepancy may relate to
differential expression of TS protein in the nucleus compared with
the cytoplasm, as is discussed below. Clonal selection is a recog-
nised component of the process of metastasis (De Both et al,
1997). As an explanation for our findings, clones of increased
nuclear TS-expressing cells may be selected for when CRCs
metastasise. The survival advantage gained by such selection is
unclear but may relate to TS’s putative role as a regulator of
several oncogenic proteins, such as c-myc. Further, TS expression
has recently been shown, in CRCs, to correlate with expression of
vascular endothelial growth factor (van Triest et al, 2000), a
compound important to the process of metastasis (Bikfalvi, 1995).
In keeping with a positive correlation between primary and
metastatic tissue TS nuclear expression, a higher TS histoscore in
CRC metastases appeared to associate with poorer response to
5FU therapy. The fact that this association did not reach statistical
significance might merely be due to a smaller sample size. 
The association between higher TS nuclear protein expression
and poorer response to 5FU therapy is in keeping with several
previous studies of advanced CRC where TS cytoplasmic protein
expression was measured by immunohistochemical or biochem-
ical techniques or TS mRNA expression was measured by
reverse transcriptase PCR (Peters et al, 1994; Johnston et al, 1995;
Lenz et al, 1998b; Paradiso et al, 2000). In support of published
data (Brett et al, 1996), none of the clinicopathological details
shown in Table 1 individually predicted for 5FU response. It
therefore seems unlikely that TS nuclear expression is only indi-
rectly associated with 5FU response via a relation with a recog-
nised clinicopathological feature of CRC. Another possible
confounding factor relates to previous work demonstrating an
association between cell proliferation indices and 5FU response
in a variety of tumour types (Ravaioli et al, 1998; Zhang et al,
1998). In view of the role of TS in DNA synthesis, it may be
speculated that the TS histoscore predicts for 5FU response
amongst primary CRCs only by acting as a cell proliferation
index. This, however, is unlikely in view of the lack of direct
association between Ki67-labelling index and 5FU response and
the poor correlation between the former and TS histoscore. This
lack of correlation in malignant tissue contrasts against the
prominence of TS nuclear expression at sites of cell proliferation
in normal tissue, as noted above. It may therefore be suggested
that, in malignancy, the expression of nuclear TS protein is
dysregulated and no longer tied closely to the level of DNA
synthesis and proliferative activity. 
There is increasing evidence of interactions between the TS and
p53 systems. As previously mentioned, TS protein has been shown to
bind to p53 mRNA, thereby reducing expression of p53 protein (Chu
et al, 1999). Trying to predict, from these findings, the association
between TS and p53 proteins in vivo is, however, complicated by
observations that wild-type p53 protein can, in turn, inhibit TS
promoter activity (Lee et al, 1997). Indeed, this second interaction
better explains the in vivo observations that p53 gene mutation and
protein overexpression (an accepted though not absolute surrogate
marker of mutant protein expression) associates with increased
TS mRNA (Lenz et al, 1998b) and cytoplasmic protein (Lenz et al,
1998a; Paradiso et al, 2000) expression amongst CRCs. We, however,
were unable to demonstrate any association between increased
nuclear TS expression and p53 overexpression. Our sample size (52
patients) was larger than those used in most previous studies, e.g. 36
(Lenz et al, 1998b) and 45 (Lenz et al, 1998a). Further, we and, for
example, Lenz and colleagues used the same monoclonal antibody
clones (TS106 for TS and DO-7 for p53) and the same definition of
p53 overexpression (greater than 10% positively stained nuclei). It
may therefore be speculated that p53 overexpression has different
effects on cytoplasmic TS expression compared with nuclear expres-
sion. Some evidence for such differential regulation of TS expression
derives from Maley and colleagues’ studies on rat hepatoma cells.
Cells exposed to increasing concentrations of fluorodeoxyuridine
show increased TS protein levels (Rhee et al, 1990) but this change is
predominantly seen in the cytoplasm as opposed to the nucleus
(Samsonoff et al, 1997). Further work will be required to clarify the
reasons for and the mechanisms underlying this differential expres-
sion of TS, if not just to help understand the interaction between p53
and the enzyme. 
In summary, we have confirmed the presence of nuclear
expression of TS protein in human colorectal tissue in vivo and
investigated associations of such expression with different clinico-
pathological features of CRC. The relatively small sample of
CRCs studied suggests our data and conclusions should be viewed
as being preliminary. However, they do point toward further
studies particularly relating to the use of nuclear TS expression to
predict for 5FU response. It would be informative to compare
nuclear against cytoplasmic TS protein expression and TS mRNA
expression as predictors of such response and survival amongst a
large cohort of CRC patients. Finally, whether measuring thymi-
dine phosphorylase (Salonga et al, 2000; van Triest et al, 2000)
and dihydropyrimidine dehydrogenase (Salonga et al, 2000)
expression improves the ability of TS nuclear expression to predict
for 5FU response also deserves investigation. 
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